The viral illness kills more people in the city than HIV, but antiviral medications may be helping cut its transmission.

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

Existing treatment criteria for chronic hepatitis B virus (HBV) infection are mainly based on data from observational studies, such as the REVEAL study from Taiwan, which was initiated in the early ...

Infection with hepatitis D viruses causes severe inflammation of the liver. An MHH team has now identified a marker on natural killer cells that is influenced by the anti-inflammatory effectiveness of ...

That is about to change, with $6 million awarded to National Cancer Centre Singapore (NCCS) senior consultant surgeon Pierce ...

Investors' focus will likely be on GILD's HIV franchise performance and oncology sales when the company reports ...

Those included, by 2030: 90% diagnosis of viral hepatitis C infection worldwide; 80% treatment of eligible candidates with chronic hepatitis C; a 90% reduction in new cases of chronic hepatitis C ...

New model predicts HCC risk in noncirrhotic chronic hepatitis B patients, improving early detection strategies.

China: A recent study published in the Annals of Hepatology has emphasized the influence of age on hepatocellular carcinoma ...

The diagnosis of hepatitis A virus (HAV ... during polyclonal activation of the immune system due to unrelated viral infection or autoimmune diseases. Molecular diagnosis of HAV along with ...

An antisense drug in development at GSK has shown further activity against hepatitis B virus ... whom the disease becomes chronic. The drug is designed to target viral DNA directly, which could ...

Viral hepatitis is a major danger to public health. According to WHO’s 2024 Global Hepatitis Report, viral hepatitis deaths increased from 1.1 million in 2019 to 1.3 million in 2022, rates now ...